HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout
- Second Milestone Achieved by HemoShear in Exclusive Drug Discovery Collaboration -
News provided by
Share this article
CHARLOTTESVILLE, Va., April 21, 2021 /PRNewswire/ --
HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has identified a second drug target for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP) that was established in January 2019. Leveraging its proprietary
REVEAL-Tx™ disease modeling platform, HemoShear has earned two milestone payments to date in accordance with the Horizon exclusive drug discovery agreement. Each milestone acknowledges the validation of a novel drug target and its advancement to a subsequent stage in Horizon's early discovery pipeline.